179 related articles for article (PubMed ID: 30586008)
1. Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis.
Banini BA; Cazanave SC; Yates KP; Asgharpour A; Vincent R; Mirshahi F; Le P; Contos MJ; Tonascia J; Chalasani NP; Kowdley KV; McCullough AJ; Behling CA; Schwimmer JB; Lavine JE; Sanyal AJ;
J Clin Gastroenterol; 2019; 53(10):750-758. PubMed ID: 30586008
[TBL] [Abstract][Full Text] [Related]
2. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
[TBL] [Abstract][Full Text] [Related]
3. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
4. Haptoglobin 2-2 Genotype is Associated with More Advanced Disease in Subjects with Non-Alcoholic Steatohepatitis: A Retrospective Study.
Zhou J; Liu J; Sheng H; You N; Chen J; Mi X; Yang W; Zang S; Shi J;
Adv Ther; 2019 Apr; 36(4):880-895. PubMed ID: 30820874
[TBL] [Abstract][Full Text] [Related]
5. Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.
Guy CD; Suzuki A; Abdelmalek MF; Burchette JL; Diehl AM;
Hepatology; 2015 Jan; 61(1):98-107. PubMed ID: 24849310
[TBL] [Abstract][Full Text] [Related]
6. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Bril F; Biernacki DM; Kalavalapalli S; Lomonaco R; Subbarayan SK; Lai J; Tio F; Suman A; Orsak BK; Hecht J; Cusi K
Diabetes Care; 2019 Aug; 42(8):1481-1488. PubMed ID: 31332029
[TBL] [Abstract][Full Text] [Related]
7. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
[TBL] [Abstract][Full Text] [Related]
9. Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin.
Gawrieh S; Harlow KE; Pike F; Yates KP; Wilson LA; Cummings OW; Rosenberg WM; Chalasani N; Molleston JP
J Pediatr; 2021 Dec; 239():161-167.e5. PubMed ID: 34400208
[TBL] [Abstract][Full Text] [Related]
10. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
11. Vitamin E and nonalcoholic fatty liver disease.
Pacana T; Sanyal AJ
Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
[TBL] [Abstract][Full Text] [Related]
12. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
[TBL] [Abstract][Full Text] [Related]
13. Ornithine Aspartate and Vitamin-E Combination Has Beneficial Effects on Cardiovascular Risk Factors in an Animal Model of Nonalcoholic Fatty Liver Disease in Rats.
de Freitas LBR; Longo L; Filippi-Chiela E; de Souza VEG; Behrens L; Pereira MHM; Leonhard LC; Zanettini G; Pinzon CE; Luchese E; Lima GJSP; Cerski CT; Uribe-Cruz C; Álvares-da-Silva MR
Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551202
[TBL] [Abstract][Full Text] [Related]
14. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
Said A; Akhter A
Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model.
Klaebel JH; Skjødt M; Skat-Rørdam J; Rakipovski G; Ipsen DH; Schou-Pedersen AMV; Lykkesfeldt J; Tveden-Nyborg P
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752351
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
17. Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial.
Costacou T; Levy AP; Miller RG; Snell-Bergeon J; Asleh R; Farbstein D; Fickley CE; Pambianco G; de la Vega R; Evans RW; Orchard TJ
Acta Diabetol; 2016 Apr; 53(2):243-50. PubMed ID: 26002590
[TBL] [Abstract][Full Text] [Related]
18. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH).
Cheng J; Joyce A; Yates K; Aouizerat B; Sanyal AJ
PLoS One; 2012; 7(9):e44106. PubMed ID: 23028489
[TBL] [Abstract][Full Text] [Related]
20. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis.
Han MAT; Altayar O; Hamdeh S; Takyar V; Rotman Y; Etzion O; Lefebvre E; Safadi R; Ratziu V; Prokop LJ; Murad MH; Noureddin M
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):616-629.e26. PubMed ID: 29913275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
